ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) has received a consensus rating of “Moderate Buy” from the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $25.56.
A number of analysts have recently issued reports on the stock. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, September 13th. Royal Bank of Canada reduced their target price on ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Cantor Fitzgerald lowered their price target on ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. Morgan Stanley lowered shares of ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $28.00 to $20.00 in a report on Wednesday, August 7th. Finally, Raymond James reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th.
Read Our Latest Analysis on ACAD
Insider Activity at ACADIA Pharmaceuticals
Institutional Trading of ACADIA Pharmaceuticals
Several large investors have recently added to or reduced their stakes in the company. Park Place Capital Corp acquired a new stake in shares of ACADIA Pharmaceuticals during the third quarter worth approximately $25,000. Covestor Ltd grew its holdings in shares of ACADIA Pharmaceuticals by 70.5% during the 1st quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 840 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of ACADIA Pharmaceuticals in the first quarter worth $48,000. Stonepine Capital Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the second quarter worth $81,000. Finally, Acadian Asset Management LLC acquired a new stake in ACADIA Pharmaceuticals during the second quarter valued at $111,000. 96.71% of the stock is owned by institutional investors and hedge funds.
ACADIA Pharmaceuticals Trading Up 0.9 %
ACAD stock opened at $15.30 on Friday. The firm has a 50-day moving average of $15.65 and a two-hundred day moving average of $16.25. ACADIA Pharmaceuticals has a 12 month low of $14.31 and a 12 month high of $32.59. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -1,530.00, a PEG ratio of 0.49 and a beta of 0.38.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.18 by $0.02. The firm had revenue of $241.96 million during the quarter, compared to analysts’ expectations of $235.95 million. ACADIA Pharmaceuticals had a return on equity of 6.89% and a net margin of 3.43%. The business’s revenue for the quarter was up 46.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.01 earnings per share. As a group, equities analysts forecast that ACADIA Pharmaceuticals will post 0.52 earnings per share for the current year.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
Read More
- Five stocks we like better than ACADIA Pharmaceuticals
- What Are Dividend Champions? How to Invest in the Champions
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What is MarketRank™? How to Use it
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How to Calculate Options Profits
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.